Eli Lilly’s engineered peptide drugs Mounjaro and Zepbound are once-weekly injectable products, formulations that are expensive to manufacture and burdensome to patients who dislike needles. Lilly just struck a deal that could ease both problems. It’s partnering with Camurus , a company with technology that enables extended dosing of injectable medicines.

The collaboration and license agreement announced late Tuesday gives Lilly exclusive global rights to develop and commercialize long-acting drugs based on the technology of Camurus. The deal terms commit Lilly to pay up to $290 million in upfront, development, and regulatory milestone payments.

The platform technology of Lund, Sweden-based Camurus, called FluidCrystal, enables an injected drug to last for extended periods. FluidCrysta

See Full Page